Investigational antiviral drugs for the treatment of COVID-19

C. T.R. Vegivinti, M. Assi, R. Talwani, V. Koblizek, K. Burke, Zelalem Temesgen

Research output: Contribution to journalReview articlepeer-review


A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.

Original languageEnglish (US)
Pages (from-to)697-710
Number of pages14
JournalDrugs of the Future
Issue number9
StatePublished - Sep 2021


  • COVID-19
  • Camostat
  • DAS-181
  • Favipiravir
  • Hydroxychloroquine
  • Ivermectin
  • Lopinavir/ritonavir
  • Nafamostat
  • Nitazoxanide
  • Remdesivir
  • Ribavirin
  • SARS-CoV-2
  • Umifenovir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Investigational antiviral drugs for the treatment of COVID-19'. Together they form a unique fingerprint.

Cite this